BC
JSPR icon

BIT Capital’s Jasper Therapeutics JSPR Stock Holding History

BIT Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,000
Closed -$57.9K – 158
2022
Q2 		$57.9K Hold
3,000
– – 0.01% 105
2022
Q1 		$107K Buy
+3,000
New +$135K 0.01% 104

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
FIM
Fernwood Investment Management Quincy, Massachusetts $288M AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIT Capital's JSPR Position: Q3 2022 in Review

BIT Capital sold out of Jasper Therapeutics (JSPR) in Q3 2022, closing a stake of 3,000 shares — an estimated $57.9K sold.

BIT Capital first reported a position in JSPR in Q1 2022 and held it in 2 quarters. The position peaked at $107K in Q1 2022. 23 funds tracked by Wall St. Rank hold JSPR as of Q3 2022.

  • BIT Capital reported no remaining Jasper Therapeutics position as of Q3 2022 after selling out during the quarter.
  • BIT Capital sold 3,000 Jasper Therapeutics shares in Q3 2022, an estimated $57.9K.
  • BIT Capital first reported a position in Jasper Therapeutics in Q1 2022 and held it in 2 quarters.
  • BIT Capital's Jasper Therapeutics position peaked at $107K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2022.

Based on BIT Capital's 13F filing for Q3 2022, filed 12 Feb 2025.